Activator protein 1-mediated transcriptional regulation strategy sustains long-term expression of a xenogeneic gene product in vivo: An implication for gene therapy targeting congenital protein deficiencies

International Journal of Molecular Medicine

Volumn 18, Issue 2, 2006, Pages 289-297

  Sasaki, Shin ^a   Smith, James M ^b   Takase, Keiko ^a   Okuda, Kenji ^a   Ishii, Norihisa ^c   Takeshita, Fumihiko ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Antibody Systems Inc   (United States)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

AP 1; Gene therapy; Promoter

Indexed keywords

TRANSCRIPTION FACTOR AP 1;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL LINE; ENHANCER REGION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSCRIPTION; HAMSTER; HUMAN; MALE; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; MOUSE; MOUSE MUTANT; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN DEFICIENCY; RAT; TRANSGENE;

ANIMALS; BASE SEQUENCE; CELL LINE; CRICETINAE; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); PROTEIN DEFICIENCY; RATS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; TRANSGENES;

EID: 39049179721     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.18.2.289     Document Type: Article

References (41)

1. Boshart M, Weber F, Jahn G, Dorsch-Hasler K, Fleckenstein B and Schaffner W: A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41: 521-530, 1985.
2. Miyazaki J, Takaki S, Araki K, Tashiro F, Tominaga A, Takatsu K and Yamamura K: Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5. Gene 79: 269-277, 1989.
3. Bettan M, Emmanuel F, Darteil R, Caillaud JM, Soubrier F, Delaere P, Branelec D, Mahfoudi A, Duverger N and Scherman D: High-level protein secretion into blood circulation after electric pulse-mediated gene transfer into skeletal muscle. Mol Ther 2: 204-210, 2000.
4. Bettan M, Darteil R and Scherman D: Secreted human placental alkaline phosphatase as a reporter gene for in vivo gene transfer. Anal Biochem 271: 187-189, 1999.
5. Chastain M, Simon AJ, Soper KA, Holder DJ, Montgomery DL, Sagar SL, Casimiro DR and Middaugh CR: Antigen levels and antibody titers after DNA vaccination. J Pharm Sci 90: 474-484, 2001.
6. Yew NS, Przybylska M, Ziegler RJ, Liu D and Cheng SH: High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol Ther 4: 75-82, 2001. (Erratum in Mol Ther 4: 280, 2001).
7. Maelandsmo GM, Ross PJ, Pavliv M, Meulenbroek RA, Evelegh C, Muruve DA, Graham FL and Parks RJ: Use of a murine secreted alkaline phosphatase as a non-immunogenic reporter gene in mice. J Gene Med 7: 307-315, 2005.
8. Gronevik E, von Steyern FV, Kalhovde JM, Tjelle TE and Mathiesen I: Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle. J Gene Med 7: 218-227, 2005.
9. Payette PJ, Weeratna RD, McCluskie MJ and Davis HL: Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanisms. Gene Ther 8: 1395-1400, 2001.
10. Scharrer I, Bray GL and Neutzling O: Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 5: 145-154, 1999.
11. Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A and Hershfield MS: IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 89: 1643-1651, 1992.
12. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, Izykowski B, Phillips J, Doroshow R, Walot I, Hoft R and Neufeld EF: Enzyme-replacement therapy in mucopolysaccharidosis I. New England J Med 344: 182-188, 2001.
13. Richards SM, Olson TA and McPherson JM: Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 82: 1402-1409, 1993.
14. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ and International Collaborative Fabry Disease Study Group: Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. New England J Med 345: 9-16, 2001.
15. Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, Mackey J, Kishnani P, Smith W, McVie-Wylie A, Sullivan JA, Hoganson GE, Phillips JA III, Schaefer GB, Charrow J, Ware RE, Bossen EH and Chen YT: Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 3: 132-138, 2001.
16. Saukkonen K and Hemminki A: Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 4: 683-696, 2004. (Pubitemid 38667814)
17. Papadakis ED, Nicklin SA, Baker AH and White SJ: Promoters and control elements: designing expression cassettes for gene therapy. Current Gene Ther 4: 89-113, 2004.
18. Ross TM, Xu Y, Bright RA and Robinson HL: C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 1: 127-131, 2000.
19. Wang M, Orsini C, Casanova D, Millan JL, Mahfoudi A and Thuillier V: MUSEAP, a novel reporter gene for the study of long-term gene expression in immunocompetent mice. Gene 279: 99-108, 2001.
20. Takeshita F, Suzuki K, Sasaki S, Ishii N, Klinman DM and Ishii KJ: Transcriptional regulation of the human TLR9 gene. J Immunol 173: 2552-2561, 2004.
21. Sasaki S, Amara RR, Oran AE, Smith JM and Robinson HL: Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat Biotechnol 19: 543-547, 2001.
22. Li Q and Verma IM: NF-kappaB regulation in the immune system. Nature Rev Immunol 2: 725-734, 2002.
23. Eferl R and Wagner EF: AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868, 2003.
24. Herweijer H and Wolff JA: Progress and prospects: naked DNA gene transfer and therapy. Gene Ther 10: 453-458, 2003.
25. Walsh CE: Gene therapy progress and prospects: gene therapy for the hemophilias. Gene Ther 10: 999-1003, 2003. (Pubitemid 36722489)
26. Cheng SH and Smith AE: Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther 10: 1275-1281, 2003.
27. Qian J, Collins M, Sharpe AH and Hoyer LW: Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 95: 1324-1329, 2000.
28. Wu H, Reding M, Qian J, Okita DK, Parker E, Lollar P, Hoyer LW and Conti-Fine BM: Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 85: 125-133, 2001.
29. Sarkar R, Gao GP, Chirmule N, Tazelaar J and Kazazian HH Jr: Partial correction of murine hemophilia A with neo-antigenic murine factor VIII. Hum Gene Ther 11: 881-894, 2000. (Pubitemid 30202479)
30. Ye P, Thompson AR, Sarkar R, Shen Z, Lillicrap DP, Kaufman RJ, Ochs HD, Rawlings DJ and Miao CH: Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol Ther 10: 117-126, 2004. (Pubitemid 38878154)
31. Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, Hagstrom JN, Pasi KJ, Ertl HC, Herzog RW and High KA: Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther 1: 225-235, 2000.
32. Herzog RW, Fields PA, Arruda VR, Brubaker JO, Armstrong E, McClintock D, Bellinger DA, Couto LB, Nichols TC and High KA: Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther 13: 1281-1291, 2002.
33. Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Cherel Y, Casadevall N, Samulski RJ and Moullier P: Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 103: 3303-3304, 2004.
34. Gao G, Lebherz C, Weiner DJ, Grant R, Calcedo R, McCullough B, Bagg A, Zhang Y and Wilson JM: Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103: 3300-3302, 2004.
35. Hess J, Angel P and Schorpp-Kistner M: AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117: 5965-5973, 2004.
36. Taniguchi T, Ogasawara K, Takaoka A and Tanaka N: IRF family of transcription factors as regulators of host defense. Ann Rev Immunol 19: 623-655, 2001.
37. Iyer M, Wu L, Carey M, Wang Y, Smallwood A and Gambhir SS: Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci USA 98: 14595-14600, 2001. (Pubitemid 33121437)
38. Ray S, Paulmurugan R, Hildebrandt I, Iyer M, Wu L, Carey M, and Gambhir SS: Novel bidirectional vector strategy for amplification of therapeutic and reporter gene expression. Hum Gene Ther 15: 681-690, 2004. (Pubitemid 38925220)
39. Nettelbeck DM, Jerome V and Muller R: A strategy for enhancing the transcriptional activity of weak cell type-specific promoters. Gene Ther 5: 1656-1664, 1998. (Pubitemid 29008336)
40. Veelken H, Leutgeb B, Kulmburg P, Fiebig H-H, Mackensen A and Lindemann A: Enhancement of a constitutively active promoter for gene therapy by a positive feed-back transcriptional activator mechanism. Int J Mol Med 2: 423-428, 1998.
41. Sadowski I, Ma J, Triezenberg S and Ptashne M: GAL4-VP16 is an unusually potent transcriptional activator. Nature 335: 563-564, 1988.